- Home
- FT vs KRRO Comparison
FT vs KRRO Comparison
Compare FT & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- KRRO
- Stock Information
- Founded
- FT 1988
- KRRO 2014
- Country
- FT United States
- KRRO United States
- Employees
- FT N/A
- KRRO N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- KRRO Health Care
- Exchange
- FT Nasdaq
- KRRO Nasdaq
- Market Cap
- FT 190.4M
- KRRO 209.6M
- IPO Year
- FT N/A
- KRRO 2019
- Fundamental
- Price
- FT $7.45
- KRRO $15.43
- Analyst Decision
- FT
- KRRO Strong Buy
- Analyst Count
- FT 0
- KRRO 7
- Target Price
- FT N/A
- KRRO $90.67
- AVG Volume (30 Days)
- FT 63.0K
- KRRO 103.7K
- Earning Date
- FT 01-01-0001
- KRRO 05-07-2025
- Dividend Yield
- FT 7.85%
- KRRO N/A
- EPS Growth
- FT N/A
- KRRO N/A
- EPS
- FT N/A
- KRRO N/A
- Revenue
- FT N/A
- KRRO $4,821,000.00
- Revenue This Year
- FT N/A
- KRRO N/A
- Revenue Next Year
- FT N/A
- KRRO $55.56
- P/E Ratio
- FT N/A
- KRRO N/A
- Revenue Growth
- FT N/A
- KRRO N/A
- 52 Week Low
- FT $5.97
- KRRO $11.13
- 52 Week High
- FT $7.23
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- FT 57.37
- KRRO 47.36
- Support Level
- FT $7.42
- KRRO $13.40
- Resistance Level
- FT $7.48
- KRRO $22.15
- Average True Range (ATR)
- FT 0.08
- KRRO 2.46
- MACD
- FT 0.03
- KRRO 0.11
- Stochastic Oscillator
- FT 89.19
- KRRO 31.09
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.